Diagnostics (Jul 2020)

Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer—The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol

  • Maik Haentschel,
  • Michael Boeckeler,
  • Irina Bonzheim,
  • Florian Schimmele,
  • Werner Spengler,
  • Franz Stanzel,
  • Christoph Petermann,
  • Kaid Darwiche,
  • Lars Hagmeyer,
  • Reinhard Buettner,
  • Markus Tiemann,
  • Hans-Ulrich Schildhaus,
  • Rainer Muche,
  • Hans Boesmueller,
  • Felix Everinghoff,
  • Robert Mueller,
  • Bijoy Atique,
  • Richard A. Lewis,
  • Lars Zender,
  • Falko Fend,
  • Juergen Hetzel

DOI
https://doi.org/10.3390/diagnostics10070459
Journal volume & issue
Vol. 10, no. 7
p. 459

Abstract

Read online

The detection of molecular alterations is crucial for the individualized treatment of advanced non-small cell lung cancer (NSCLC). Missing targetable alterations may have a major impact on patient’s progression free and overall survival. Although laboratory testing for molecular alterations has continued to improve; little is known about how biopsy technique affects the detection rate of different mutations. In the retrospective study detection rate of epidermal growth factor (EGFR) mutations in tissue extracted by bronchoscopic cryobiopsy (CB was significantly higher compared to other standard biopsy techniques. This prospective, randomized, multicenter, single blinded study evaluates the accuracy of molecular genetic characterization of NSCLC for different cell sampling techniques. Key inclusion criteria are suspected lung cancer or the suspected relapse of known NSCLC that is bronchoscopically visible. Patients will be randomized, either to have a CB or a bronchoscopic forceps biopsy (FB). If indicated, a transbronchial needle aspiration (TBNA) of suspect lymph nodes will be performed. Blood liquid biopsy will be taken before tissue biopsy. The primary endpoint is the detection rate of molecular genetic alterations in NSCLC, using CB and FB. Secondary endpoints are differences in the combined detection of molecular genetic alterations between FB and CB, TBNA and liquid biopsy. This trial plans to recruit 540 patients, with 178 evaluable patients per study cohort. A histopathological and molecular genetic evaluation will be performed by the affiliated pathology departments of the national network for genomic medicine in lung cancer (nNGM), Germany. We will compare the diagnostic value of solid tumor tissue, lymph node cells and liquid biopsy for the molecular genetic characterization of NSCLC. This reflects a real world clinical setting, with potential direct impact on both treatment and survival.

Keywords